Perioperative Management of Fenofibrate

Bleeding Risk Assessment

The American College of Chest Physicians recommends discontinuing fenofibrate 24 hours before surgery for low-to-moderate bleeding risk procedures and 48-72 hours before high bleeding risk procedures due to potential bleeding complications 1, 2
High bleeding risk procedures, such as major vascular surgery, cardiac, intracranial, or spinal surgery, and surgery in highly vascular organs, require discontinuation of fenofibrate 48-72 hours before surgery 1, 2
Low-to-moderate bleeding risk procedures, such as arthroscopy, cutaneous/lymph node biopsies, and foot/hand surgery, require discontinuation of fenofibrate 24 hours before surgery 2, 3
Neuraxial anesthesia or epidural injections are considered high bleeding risk procedures and require discontinuation of fenofibrate 48-72 hours before surgery 1, 3

Perioperative management of lipid-lowering medications, including fenofibrate, generally follows a cautious approach to minimize potential complications 2

The American Society of Hematology recommends resuming fenofibrate 24 hours after low-to-moderate bleeding risk procedures and 48-72 hours after high bleeding risk procedures 4

Patients on anticoagulant therapy require a consensus of the surgeon, anesthesiologist, and other specialists involved in the patient's care to determine management 5
Emergency procedures require consultation with specialists to determine the best course of action 2
Restarting fenofibrate at the appropriate time postoperatively is crucial to maintain lipid control 4